ST
STVN.US Stevanato Group SpA
- Market cap
- USD 4.17B
- P/E
- 25.8x
- P/B
- 2.41x
- ROE
- 7.7%
- Dividend yield
- 0.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STVN.US undervalued?
Graham numberSTVN.US trades 66.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stevanato Group SpA fundamental analysis
No fundamental analysis for Stevanato Group SpA yet.
Stevanato Group SpA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stevanato Group SpA
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic s…
Full company profileStevanato Group SpA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stevanato Group SpA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 537M | 662M | 844M | 984M | 1.09B | 1.10B | 1.14B | 1.20B |
| Gross Profit | 138M | 194M | 265M | 320M | 340M | 302M | 330M | 342M |
| Operating Income | 62.2M | 103M | 162M | 192M | 201M | 161M | 183M | 180M |
| EBITDA | 107M | 156M | 227M | 256M | 272M | 248M | 292M | 282M |
| Net Income | 39.2M | 78.5M | 134M | 143M | 146M | 118M | 134M | 123M |
| EPS | 0.15 | 0.30 | 0.51 | 0.54 | 0.55 | 0.43 | 0.49 | 0.45 |
| Balance Sheet | ||||||||
| Total Assets | 882M | 968M | 1.42B | 1.66B | 2.07B | 2.33B | 2.54B | 2.67B |
| Total Liabilities | 617M | 658M | 577M | 664M | 939M | 924M | 1.06B | 1.07B |
| Shareholders' Equity | 265M | 310M | 842M | 996M | 1.13B | 1.40B | 1.49B | 1.59B |
| Cash & Short-term Investments | 126M | 157M | 438M | 257M | 70.4M | 98.3M | 133M | 116M |
| Total Debt | 376M | 363M | 244M | 218M | 397M | 429M | 471M | 469M |
| Cash Flow | ||||||||
| Operating Cash Flow | 42.6M | 156M | 133M | 103M | 105M | 156M | 275M | 218M |
| Capital Expenditure | 73.9M | 96.0M | 113M | 243M | 442M | 314M | 253M | 224M |
| Free Cash Flow | -31.3M | 59.7M | 20.1M | -140M | -337M | -158M | 21.4M | -6.30M |
| Ratios | ||||||||
| ROE | 14.8% | 25.3% | 16.0% | 14.3% | 12.9% | 8.4% | 9.0% | 7.7% |
| ROA | 4.4% | 8.1% | 9.5% | 8.6% | 7.0% | 5.1% | 5.3% | 4.6% |
| Net Profit Margin | 7.3% | 11.9% | 15.9% | 14.5% | 13.4% | 10.7% | 11.8% | 10.3% |
| Debt to Equity | 1.42x | 1.17x | 0.29x | 0.22x | 0.35x | 0.31x | 0.32x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stevanato Group SpA dividends
- Dividend yield
- 0.40%
- Forward dividend
- 0.06 USD
- Payout ratio
- 10.5%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 14.2M | 0.05 | 10.5% |
| 2024 | EUR 14.5M | 0.05 | 12.3% |
| 2023 | EUR 14.3M | 0.05 | 9.8% |
| 2022 | EUR 13.5M | 0.05 | 9.5% |
| 2021 | EUR 11.2M | 0.04 | 8.3% |
| 2020 | EUR 8.90M | 0.03 | 11.3% |
| 2019 | EUR 6.17M | 0.02 | 15.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Stevanato Group SpA
- Insiders 1.87%
- Institutions 98.13%
- Public & others 0.00%
- Shares outstanding 49.8M
- Free float 49.0M
Top funds holding STVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Neuberger Genesis Inv | 3.04M | 1.11% | -4.12% | Sep 2026 |
| Conestoga Small Cap Investors | 2.38M | 0.87% | -14.94% | Sep 2026 |
| Baron Discovery Institutional | 1.68M | 0.62% | 0.00% | Sep 2026 |
| DPAM B Eqs NewGems Sust A EUR Dis | 1.30M | 0.48% | 0.00% | Jul 2026 |
| American Century Small Cap Growth Inv | 978K | 0.36% | 0.00% | Sep 2026 |
| Artisan Small Cap Investor | 813K | 0.30% | -2.94% | Sep 2026 |
| Polar Capital Glb Healthcare Ord | 660K | 0.24% | 0.00% | Sep 2026 |
| AMG TimesSquare Mid Cap Growth Z | 621K | 0.23% | 0.00% | Oct 2026 |
| First Eagle Small Cap Opportunity I | 596K | 0.22% | -3.49% | Sep 2026 |
| Nicholas II I | 515K | 0.19% | 0.00% | Jun 2026 |
| Ave Maria Value | 510K | 0.19% | 0.00% | Sep 2026 |
| Conestoga SMid Cap Investors | 492K | 0.18% | -19.22% | Sep 2026 |
| Royce Small-Cap Trust | 488K | 0.18% | -0.15% | Sep 2026 |
| FAM Small Cap Investor | 465K | 0.17% | 0.00% | Sep 2026 |
| Royce Small-Cap Fund Invmt | 414K | 0.15% | -0.15% | Sep 2026 |
| T. Rowe Price New Horizons | 409K | 0.15% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 387K | 0.14% | -0.19% | Oct 2026 |
| Baron Generational Growth Retail | 364K | 0.13% | 0.00% | Sep 2026 |
| JNL Multi-Manager Small Cap Growth A | 343K | 0.13% | 0.00% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 339K | 0.12% | -3.25% | Sep 2026 |
Top institutions holding STVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Conestoga Capital Advisors, LLC | 7.01M | 2.57% | -17.48% | Jun 2026 |
| Neuberger Berman Group LLC | 5.62M | 2.06% | +25.62% | Jun 2026 |
| TimesSquare Capital Management, LLC | 3.25M | 1.19% | -6.38% | Sep 2026 |
| Van Berkom and Associates Inc | 2.86M | 1.05% | -3.73% | Sep 2026 |
| Artisan Partners Limited Partnership | 2.60M | 0.95% | +13.60% | Jun 2026 |
| BAMCO Inc | 2.49M | 0.91% | -0.22% | Jun 2026 |
| American Century Companies Inc | 1.65M | 0.61% | 0.00% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 1.31M | 0.48% | -0.85% | Jun 2026 |
| Crédit Agricole S.A. | 1.30M | 0.48% | +249.36% | Jun 2026 |
| Wellington Management Company LLP | 1.25M | 0.46% | 0.00% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 1.22M | 0.45% | +676.24% | Jun 2026 |
| Ranger Investment Management LP | 1.19M | 0.43% | -6.64% | Jun 2026 |
| Royce & Associates, LP | 916K | 0.34% | +8.92% | Jun 2026 |
| Deutsche Bank AG | 834K | 0.31% | -1.77% | Jun 2026 |
| New York State Common Retirement Fund | 792K | 0.29% | +82.64% | Jun 2026 |
| Nicholas Company Inc | 744K | 0.27% | 0.00% | Sep 2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 696K | 0.25% | -33.46% | Jun 2026 |
| Cooper Investors Pty Limited | 668K | 0.24% | +4.41% | Jun 2026 |
| Riverbridge Partners LLC | 626K | 0.23% | +4.23% | Sep 2026 |
| Mutual Of America Capital Management LLC | 612K | 0.22% | -5.29% | Jun 2026 |
Stevanato Group SpA company profile
- Company name
- Stevanato Group SpA
- Ticker
- STVN.US
- ISIN
- IT0005452658
- Exchange
- USA Stocks
- Listed since
- Jul 16, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,010
- Fiscal year end
- December
- Address
- Via Molinella 17, Piombino Dese, PD, Italy, 35017
- Phone
- 39 04 99 31 811
- Website
- stevanatogroup.com
About Stevanato Group SpA
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Stevanato Group SpA management
10- Mr. Franco StevanatoCEO & Executive Chairman · born 1973
- Mr. Marco Dal LagoChief Financial Officer · born 1973
- Ms. Lisa MilesChief Communications & Investor Relations Officer
- Ms. Carla CostaChief Human Resources Officer
- Mr. Mauro StocchiChief Business Strategy Officer · born 1966
- Mr. Michele MonicoPresident of DDS & IVD Business Unit
- Mr. Alberto CagnatoSenior Vice President of DCS Operations
- Mr. Riccardo MarconSenior Vice President of Sales & Marketing of DCS
- Ms. Veda K. Walcott CLS (NCA), MBA, MT (ASCP)Chief Quality & Regulatory Officer
- Mr. Alessandro MelchiorrePresident of Engineering Business Unit